Invasive Carcinoma — Trials

Invasive Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,813 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 604
Recruiting: 302
Ph III recruiting: 37
Growth YoY: +27.2%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (282)

clinicaltrialsPublishedShowing 501–550 of 1,813 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	Phase 2	10	CanariaBio Inc.INDUSTRY	1	Apr 3, 2026	clinicaltrials
NCT04569747	A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT)	active not recruiting	Phase 2	393	Dana-Farber Cancer InstituteOTHER